Corticotropin is a Small Molecule owned by ANI Pharmaceuticals, and is involved in 1 clinical trial, which was completed.
Corticotropin and endogenous adrenocorticotropic hormone ACTH) stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances.
The revenue for Corticotropin is expected to reach a total of $3.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Corticotropin NPV Report.
Corticotropin is currently owned by ANI Pharmaceuticals.
Corticotropin Overview
Corticotropin (Purified Cortrophin) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It is formulated as solution for intramuscular or subcutaneous route of administration. Purified Cortrophin is indicated for the treatment of infantile spasms, multiple sclerosis (acute exacerbations of multiple sclerosis), rheumatic disorders (Psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis), collagen diseases (systemic lupus erythematosus, systemic dermatomyositis (polymyositis)), dermatologic diseases (severe erythema multiforme, Stevens-Johnson syndrome), allergic states (Serum sickness), ophthalmic diseases (keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation), respiratory diseases (symptomatic sarcoidosis) and edematous states (proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus).
ANI Pharmaceuticals Overview
ANI Pharmaceuticals (ANI) is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals. The company offers pharmaceuticals for central nervous system (CNS) disorders, gastrointestinal, cancer, ophthalmic, metabolic and other diseases. ANI also conducts business as a Contract Development and Manufacturing Organization (CDMO) supporting late-stage development to commercial manufacture of pharmaceutical products including coated/non-coated tablets and capsules, ointments, creams, non-sterile liquids, suspensions, and gels. It markets oncology products, complex formulations, hormones and steroids and controlled substances. The company sells products to wholesale distributors, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. ANI is headquartered in Baudette, Minnesota, the US.
The company reported revenues of (US Dollars) US$216.1 million for the fiscal year ended December 2021 (FY2021), an increase of 3.7% over FY2020. The operating loss of the company was US$39.8 million in FY2021, compared to an operating loss of US$16 million in FY2020. The net loss of the company was US$42.6 million in FY2021, compared to a net loss of US$22.6 million in FY2020.
The company reported revenues of US$83.8 million for the third quarter ended September 2022, an increase of 13.5% over the previous quarter.
Quick View – Corticotropin
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|